Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 44.8%

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 76,808 shares, a growth of 44.8% from the January 15th total of 53,042 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 462,687 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 462,687 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC boosted its stake in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC purchased a new stake in SOPHiA GENETICS in the 3rd quarter valued at about $6,708,000. Royce & Associates LP acquired a new position in shares of SOPHiA GENETICS during the 4th quarter valued at about $2,009,000. Finally, Archon Capital Management LLC purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter worth about $997,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analysts Set New Price Targets

SOPH has been the topic of several recent research reports. Wall Street Zen upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Saturday, November 1st. Guggenheim upped their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. BTIG Research increased their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS has an average rating of “Hold” and an average target price of $7.00.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH opened at $4.74 on Tuesday. The company has a 50-day simple moving average of $4.94 and a 200-day simple moving average of $4.33. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.80 and a quick ratio of 2.62. The company has a market cap of $320.33 million, a PE ratio of -10.30 and a beta of 1.11. SOPHiA GENETICS has a 12 month low of $2.58 and a 12 month high of $5.70.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.